Neogen Chemicals Limited
Chemicals · NSE
↓ 260.4% vs fair value
52W Low
₹967
+23.6% from low
52W High
₹1,797
-33.5% from high
Valuation Gauge
Current Price
₹1,195
Fair Value
₹332
Fair Value Analysis
₹332
Based on balance sheet strength analysis and earnings growth potential for Chemicals sector companies | CAUTION: ROCE declining (latest 9.8%) — returns on capital are falling; verify this isn't a value trap. | Growth capped at 7.4% (ROE 6.4%×1.15) — historical CAGR exceeds sustainable rate or COVID period unverifiable.
Balance Sheet Value
60% weight
Growth Valuation
40% weight
Price vs Market
Shareholding Pattern
Stock Health Score
Mixed Signals
Profitability
ROE of 6.4% is below the Chemicals sector benchmark of 15%
Debt & Leverage
D/E ratio of 1.4x is manageable for Chemicals sector (norm: 0.8x)
Valuation vs Peers
P/E of 61.5x is in line with the Chemicals sector median of 64x — fairly valued
Cash Flow
Negative FCF of ₹-122 Cr — company is consuming more cash than it generates
Earnings Growth
5yr EPS CAGR of -7.9% — earnings are declining (sector avg growth: 14.1%)
Dividend
Dividend yield of 0.1% is symbolic — low but positive
Sentiment Trend — Last 30 Days
Historical Returns
Key Ratios & Growth
FCF Yield
-3.9%
Free cash flow / market cap
Revenue Growth (YoY)
+14.3%
Year-on-year revenue change
Profit Growth (YoY)
+42.5%
Year-on-year PAT change
Operating Cash Flow
₹196 Cr
TTM cash from operations
Key Financials
EPS (TTM)
₹19.4
P/E Ratio
61.5x
P/B Ratio
3.9x
ROE
6.4%
ROCE
8.7%
Debt / Equity
1.41x
Beta
0.22
Div Yield
0.1%
FCF (Cr)
₹-122 Cr
Revenue (Cr)
₹758 Cr
EPS Growth 5Y
-7.9%
Mkt Cap (Cr)
₹3,152 Cr
52W High
₹1,797
52W Low
₹966.7
Book Value/Share
₹303.2
Financial History
| Period | Revenue | Op Profit | OPM% | PAT | EPS |
|---|---|---|---|---|---|
| TTM | ₹818 Cr | ₹130 Cr | 16.0% | ₹20 Cr | ₹7.48 |
| 2025-03-31 | ₹778 Cr | ₹136 Cr | 18.0% | ₹35 Cr | ₹13.20 |
| 2024-03-31 | ₹691 Cr | ₹110 Cr | 16.0% | ₹36 Cr | ₹13.51 |
| 2023-03-31 | ₹686 Cr | ₹112 Cr | 16.0% | ₹50 Cr | ₹20.04 |
| 2022-03-31 | ₹487 Cr | ₹87 Cr | 18.0% | ₹45 Cr | ₹17.90 |
| 2021-03-31 | ₹336 Cr | ₹64 Cr | 19.0% | ₹31 Cr | ₹13.43 |
| 2020-03-31 | ₹306 Cr | ₹58 Cr | 19.0% | ₹29 Cr | ₹12.28 |
| 2019-03-31 | ₹239 Cr | ₹43 Cr | 18.0% | ₹21 Cr | ₹10.43 |
| 2018-03-31 | ₹161 Cr | ₹29 Cr | 18.0% | ₹11 Cr | ₹5.49 |
| 2017-03-31 | ₹110 Cr | ₹20 Cr | 18.0% | ₹8 Cr | ₹3.84 |
| 2016-03-31 | ₹100 Cr | ₹14 Cr | 14.0% | ₹5 Cr | ₹2.59 |
| 2015-03-31 | ₹84 Cr | ₹13 Cr | 15.0% | ₹5 Cr | ₹11.31 |
| 2014-03-31 | ₹74 Cr | ₹11 Cr | 16.0% | ₹4 Cr | ₹8.09 |
Compounded Growth Rates
Sales Growth
Profit Growth
EPS Growth
Peer Comparison
Chemicals| Stock | Price | Fair Value | MoS% | P/E | ROE | Signal |
|---|---|---|---|---|---|---|
Madras Fertilizers Limited | ₹60 | ₹246.1 | +75.6% | 130.7 | 451.3% | UNDERVALUED |
ShreeOswal Seeds And Chemicals Limited | ₹10.8 | ₹41.2 | +73.8% | 26.9 | 11.8% | UNDERVALUED |
Kothari Petrochemicals Limited | ₹117.5 | ₹310.2 | +62.1% | 9 | 86.4% | UNDERVALUED |
Kothari Sugars And Chemicals Limited | ₹24.1 | ₹45.6 | +47.0% | 37.2 | 12.9% | UNDERVALUED |
Agro Phos India Limited | ₹31 | ₹54.2 | +42.8% | 11.2 | 13.9% | UNDERVALUED |
Aries Agro Limited | ₹358.4 | ₹620.4 | +42.2% | 10.3 | 9.9% | UNDERVALUED |
Epigral Limited | ₹905 | ₹1,514.2 | +40.2% | 11.3 | 14.8% | UNDERVALUED |
Deepak Fertilizers and Petrochemicals Corporation Limited | ₹982.5 | ₹1,402 | +29.9% | 14.3 | 13.5% | UNDERVALUED |
Institutional Activity
Bulk deals, block deals, short selling & delivery volume — NSE data
Insider Trading
Company Documents
Annual reports, concall transcripts & regulatory filings
Share this Stock
Download card · Share on WhatsApp
Share on WhatsApp, Twitter, or any group — each share brings new users to Veritas Quant
Search Interest
Google Trends · India · Last 90 days
Trend data not yet available — check back soon.
StockTwits
What traders are saying right now
No StockTwits activity found for NEOGEN.
Telegram Channels
ET Markets · CNBC TV18 · Moneycontrol · Zee Business · NDTV Profit
No Telegram mentions found yet for NEOGEN.
What is Dalal Street saying?
r/IndiaInvestments · r/Dalal_Street_Investments · r/IndianStockMarket
No Reddit mentions found yet for NEOGEN.
Neogen Corporation (NEOG) Stock forecasts - Yahoo Finance UK
Neogen Leadership Change Puts Governance And Compliance Execution In Focus - Sahm
Neogen Chemicals Ltd Opens 7.81% Higher Amid Mixed Technical Signals - Markets Mojo
Earnings Outlook: Neogen (NEOG) Anticipated Q3 Profit Decrease - Bitget
Why Neogen’s Stock Is Suddenly Sinking Hard - TipRanks
Neogen Leadership Change Puts Governance And Compliance Execution In Focus - simplywall.st
Neogen Chemicals Ltd Surges 7.54% to Day's High of Rs 1198.9 — Outperforms Sector by 2.38 Percentage Points - Markets Mojo
How Neogen Corporation (NEOG) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Neogen Announces Departure of Chief Legal Officer Rocklin - TipRanks
Neogen schedules April 9 webcast for third-quarter FY2026 results - Stock Titan
Neogen Chemicals Conducts EGM for Preferential Equity Share Issuance to Promoter Group - scanx.trade
Neogen Chemicals - Concurrent Losers: 13 small-cap stocks decline for 5 consecutive sessions - The Economic Times
Neogen Chemicals Ltd is Rated Strong Sell - Markets Mojo
Enovis, Neogen, Humana, LifeStance Health Group, and Hims & Hers Health stocks trade down, what you need to know - MSN
Enovis, Neogen, Humana, LifeStance Health Group, and Hims & Hers Health Stocks Trade Down, What You Need To Know - Yahoo Finance
Vanguard realignment leads to separate reporting; 0 NEOG shares (NEOG) - Stock Titan
Neogen Corp. Stock Hits Day Low of $8.24 Amid Price Pressure - Markets Mojo
Neogen Chemicals Ltd Upgraded to Sell on Technical Improvements Despite Weak Financials - Markets Mojo
Where is Neogen Corporation (NEOG) headed? - MSN
CIBC Bancorp USA Inc. Makes New $28.97 Million Investment in Neogen Corporation $NEOG - MarketBeat
Technical Pulse
Plain English — no jargon
Not enough price history to assess trend.
RSI is 42 — neutral momentum, neither overbought nor oversold.
Insufficient data for short-term trend.
Trading significantly above fair value. Unless you believe the business has permanently re-rated, the risk-reward is unfavorable here.